PALI Form 4: 9.18M RSUs granted to director/officer
Rhea-AI Filing Summary
Palisade Bio reported that John David Finley, a director and officer (CEO, CFO), was granted 9,179,400 restricted stock units (RSUs) on 10/06/2025. Each RSU converts to one share of common stock when settled, though RSUs may be paid in cash if there are not enough shares reserved under the 2021 Equity Incentive Plan. The RSUs vest 1/3 on 10/06/2026 and then quarterly over the next eight quarters, conditioned on continuous service. The reported grant has a $0 per-share exercise/settlement price and is held directly by the reporting person.
Positive
- 9,179,400 RSU grant aligns CEO/Officer incentives with shareholder value through multi-period vesting
- Structured vesting (1/3 on 10/06/2026, then quarterly) encourages continued service over ~2 years
Negative
- Potential dilution of 9,179,400 shares if RSUs are settled in stock, which could affect per-share metrics
- Cash settlement risk exists if plan reserves are insufficient, creating potential near-term cash outflow
Insights
Large CEO/Officer equity grant ties compensation to long-term service.
The grant of 9,179,400 RSUs is a sizeable equity award to a reporting person who serves as both a director and an officer, aligning part of compensation with future equity value because each RSU converts to one share upon settlement. Vesting is structured with a one-year cliff followed by quarterly vesting over two years, which encourages continued service through 10/06/2026 and the subsequent eight quarters.
Key dependencies include the availability of shares under the 2021 Equity Incentive Plan—if shares are unavailable, settlement may occur in cash, altering dilution and cash needs. Monitor the company’s equity reserve updates and filings over the next 12 months for impacts on outstanding shares and governance disclosures.
The award creates potential near-term dilution or cash settlement exposure.
Because the RSUs represent 9,179,400 underlying shares with a $0 stated price, the grant will either increase outstanding shares if settled in stock or require cash outflow if settled in cash when plan reserves are insufficient. The vesting schedule (one‑third on 10/06/2026, then quarterly over eight quarters) phases the potential dilution or cash impact across roughly two years.
Watch quarterly disclosure of shares reserved under the equity plan and subsequent Form 4/Form 5 entries to quantify actual dilution or cash payments within the next 24 months. A follow-up disclosure will show whether settlement occurs in stock or cash.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 9,179,400 | $0.00 | -- |
Footnotes (1)
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
